Pfizer announces a first-line combination Rx for advanced RCC.

 

NOW APPROVED
new, first-line immunotherapy (IO) and tyrosine kinase inhibitor (TKI) combination for patients with advanced renal cell carcinoma (RCC)
Learn more ›
Source View PDF